Abbott Laboratories (ABT)Abbott Laboratories (<a href=http://www.zacks.com/stock/quote/abt>ABT</a>) discovers, develops, manufactures and sells a diversified line of healthcare products. We expect high-single digit EPS growth over the next five years driven by strong sales of Humira and the company's rapidly growing vascular business. <p> Several new drug applications have recently been filed with the FDA which should accelerate sales in the pharmaceutical business. We believe ABT possesses a low risk profile and will continue to trade at an industry premium. <p> Accordingly, we reiterate our Buy recommendation with a price target of $65.
January 29, 2009 | Filed Under Stock Picks